Henry Schein (NASDAQ:HSIC) Releases FY 2026 Earnings Guidance

Henry Schein (NASDAQ:HSIC) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.230-5.370 for the period, compared to the consensus estimate of 5.280. The company issued revenue guidance of $13.6 billion-$13.8 billion, compared to the consensus revenue estimate of $13.5 billion.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on HSIC shares. Barclays started coverage on Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price on the stock. Robert W. Baird set a $100.00 price objective on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Monday. JPMorgan Chase & Co. boosted their target price on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Henry Schein has a consensus rating of “Hold” and a consensus target price of $78.75.

Henry Schein Stock Performance

HSIC opened at $80.57 on Tuesday. The stock’s 50 day simple moving average is $77.43 and its 200-day simple moving average is $71.78. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The stock has a market cap of $9.49 billion, a PE ratio of 25.50, a P/E/G ratio of 2.37 and a beta of 0.88. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.80.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts forecast that Henry Schein will post 4.74 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein during the second quarter valued at approximately $25,000. MUFG Securities EMEA plc acquired a new position in shares of Henry Schein in the 2nd quarter worth approximately $27,000. Federated Hermes Inc. acquired a new position in shares of Henry Schein in the 4th quarter worth approximately $32,000. Los Angeles Capital Management LLC bought a new position in shares of Henry Schein during the 4th quarter worth approximately $37,000. Finally, Palisade Asset Management LLC acquired a new stake in Henry Schein in the 3rd quarter valued at $100,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.